SUTRO BIOPHARMA, INC. General and Administrative Expense
SUTRO BIOPHARMA, INC. (STRO) reported General and Administrative Expense of $7.83 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GeneralAndAdministrativeExpense · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. general and administrative expense for the quarter ending 2026-06-30 was $7.83M, a 24.29% decline year-over-year.
- SUTRO BIOPHARMA, INC. general and administrative expense for the quarter ending 2026-03-31 was $7.58M, a 42.86% decline year-over-year.
- SUTRO BIOPHARMA, INC. general and administrative expense for the quarter ending 2025-12-31 was $8.66M, a 4.08% decline year-over-year.
- SUTRO BIOPHARMA, INC. general and administrative expense for the quarter ending 2025-09-30 was $8.74M, a 39.01% decline year-over-year.
- SUTRO BIOPHARMA, INC. general and administrative expense for fiscal 2025 was $41.02M, a 15.34% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. general and administrative expense for fiscal 2024 was $48.45M, a 22.58% decline from fiscal 2023.
- SUTRO BIOPHARMA, INC. general and administrative expense for fiscal 2023 was $62.58M, a 5.11% increase from fiscal 2022.
- SUTRO BIOPHARMA, INC. general and administrative expense for fiscal 2022 was $59.54M, a 6.32% increase from fiscal 2021.
| Period end | General and Administrative Expense 3 month | General and Administrative Expense 6 month | General and Administrative Expense 9 month | General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.83M 10-Q · filed 2026-08-12 | $15.41M 10-Q · filed 2026-08-12 | $24.08M derived: sum of 3 quarters · filed 2026-08-12 | $32.82M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $7.58M 10-Q · filed 2026-05-14 | $16.25M derived: sum of 2 quarters · filed 2026-05-14 | $24.99M derived: sum of 3 quarters · filed 2026-05-14 | $35.33M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $8.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $17.40M derived: sum of 2 quarters · filed 2026-03-23 | $27.75M derived: sum of 3 quarters · filed 2026-08-12 | $41.02M 10-K · filed 2026-03-23 |
| 2025-09-30 | $8.74M 10-Q · filed 2025-11-06 | $19.08M derived: sum of 2 quarters · filed 2026-08-12 | $32.36M 10-Q · filed 2025-11-06 | $41.39M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $10.34M 10-Q · filed 2026-08-12 | $23.62M 10-Q · filed 2026-08-12 | $32.65M derived: sum of 3 quarters · filed 2026-08-12 | $46.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $13.27M 10-Q · filed 2026-05-14 | $22.30M derived: sum of 2 quarters · filed 2026-05-14 | $36.63M derived: sum of 3 quarters · filed 2026-05-14 | $49.01M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $9.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $23.36M derived: sum of 2 quarters · filed 2026-03-23 | $35.73M derived: sum of 3 quarters · filed 2026-03-23 | $48.45M 10-K · filed 2026-03-23 |
| 2024-09-30 | $14.33M 10-Q · filed 2025-11-06 | $26.70M derived: sum of 2 quarters · filed 2025-11-06 | $39.42M 10-Q · filed 2025-11-06 | $56.23M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $12.37M 10-Q · filed 2025-08-07 | $25.09M 10-Q · filed 2025-08-07 | $41.90M derived: sum of 3 quarters · filed 2025-08-07 | $57.16M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $12.72M 10-Q · filed 2025-05-08 | $29.52M derived: sum of 2 quarters · filed 2025-05-08 | $44.79M derived: sum of 3 quarters · filed 2025-05-08 | $59.79M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $16.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $32.07M derived: sum of 2 quarters · filed 2025-03-13 | $47.07M derived: sum of 3 quarters · filed 2025-03-13 | $62.58M 10-K · filed 2025-03-13 |
| 2023-09-30 | $15.27M 10-Q · filed 2024-11-13 | $30.27M derived: sum of 2 quarters · filed 2024-11-13 | $45.78M 10-Q · filed 2024-11-13 | $60.50M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $15.00M 10-Q · filed 2024-08-13 | $30.51M 10-Q · filed 2024-08-13 | $45.23M derived: sum of 3 quarters · filed 2025-03-13 | $59.87M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $15.51M 10-Q · filed 2024-05-13 | $30.23M derived: sum of 2 quarters · filed 2025-03-13 | $44.87M derived: sum of 3 quarters · filed 2025-03-13 | $60.02M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $14.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $29.36M derived: sum of 2 quarters · filed 2025-03-13 | $44.51M derived: sum of 3 quarters · filed 2025-03-13 | $59.54M 10-K · filed 2025-03-13 |
| 2022-09-30 | $14.64M 10-Q · filed 2023-11-13 | $29.79M derived: sum of 2 quarters · filed 2023-11-13 | $44.83M 10-Q · filed 2023-11-13 | $60.59M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | $15.14M 10-Q · filed 2023-08-10 | $30.18M 10-Q · filed 2023-08-10 | $45.95M derived: sum of 3 quarters · filed 2024-03-25 | $62.53M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | $15.04M 10-Q · filed 2023-05-15 | $30.80M derived: sum of 2 quarters · filed 2024-03-25 | $47.39M derived: sum of 3 quarters · filed 2024-03-25 | $59.94M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | $15.76M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $32.35M derived: sum of 2 quarters · filed 2024-03-25 | $44.90M derived: sum of 3 quarters · filed 2024-03-25 | $56.00M 10-K · filed 2024-03-25 |
| 2021-09-30 | $16.59M 10-Q · filed 2022-11-08 | $29.13M derived: sum of 2 quarters · filed 2022-11-08 | $40.24M 10-Q · filed 2022-11-08 | $50.62M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-06-30 | $12.54M 10-Q · filed 2022-08-08 | $23.65M 10-Q · filed 2022-08-08 | $34.03M derived: sum of 3 quarters · filed 2023-03-30 | $43.11M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-03-31 | $11.11M 10-Q · filed 2022-05-09 | $21.49M derived: sum of 2 quarters · filed 2023-03-30 | $30.57M derived: sum of 3 quarters · filed 2023-03-30 | $39.21M derived: sum of 4 quarters · filed 2023-03-30 |
| 2020-12-31 | $10.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $19.46M derived: sum of 2 quarters · filed 2023-03-30 | $28.11M derived: sum of 3 quarters · filed 2023-03-30 | $36.82M 10-K · filed 2023-03-30 |
| 2020-09-30 | $9.08M 10-Q · filed 2021-11-10 | $17.72M derived: sum of 2 quarters · filed 2021-11-10 | $26.43M 10-Q · filed 2021-11-10 | $35.13M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $8.64M 10-Q · filed 2021-08-09 | $17.36M 10-Q · filed 2021-08-09 | $26.05M derived: sum of 3 quarters · filed 2022-02-28 | $34.17M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $8.71M 10-Q · filed 2021-05-07 | $17.41M derived: sum of 2 quarters · filed 2022-02-28 | $25.52M derived: sum of 3 quarters · filed 2022-02-28 | $33.59M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $8.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $16.81M derived: sum of 2 quarters · filed 2022-02-28 | $24.88M derived: sum of 3 quarters · filed 2022-02-28 | $32.59M 10-K · filed 2022-02-28 |
| 2019-09-30 | $8.12M 10-Q · filed 2020-11-05 | $16.18M derived: sum of 2 quarters · filed 2020-11-05 | $23.90M 10-Q · filed 2020-11-05 | $31.47M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | $8.07M 10-Q · filed 2020-08-06 | $15.78M 10-Q · filed 2020-08-06 | $23.36M derived: sum of 3 quarters · filed 2021-03-18 | $28.71M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | $7.71M 10-Q · filed 2020-05-11 | $15.29M derived: sum of 2 quarters · filed 2021-03-18 | $20.64M derived: sum of 3 quarters · filed 2021-03-18 | $24.68M derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | $7.57M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $12.93M derived: sum of 2 quarters · filed 2021-03-18 | $16.97M derived: sum of 3 quarters · filed 2021-03-18 | $21.38M 10-K · filed 2021-03-18 |
| 2018-09-30 | $5.35M 10-Q · filed 2019-11-08 | $9.39M derived: sum of 2 quarters · filed 2019-11-08 | $13.81M 10-Q · filed 2019-11-08 | $17.87M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $4.04M 10-Q · filed 2019-08-14 | $8.46M 10-Q · filed 2019-08-14 | $12.52M derived: sum of 3 quarters · filed 2020-03-16 | $17.42M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | $4.41M 10-Q · filed 2019-05-15 | $8.48M derived: sum of 2 quarters · filed 2020-03-16 | $13.38M derived: sum of 3 quarters · filed 2020-03-16 | |
| 2017-12-31 | $4.07M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $8.96M derived: sum of 2 quarters · filed 2020-03-16 | $16.37M 10-K · filed 2020-03-16 | |
| 2017-09-30 | $4.89M 10-Q · filed 2018-11-14 | $12.31M 10-Q · filed 2018-11-14 | ||
| 2016-12-31 | $14.82M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |